Pembrolizumab holds an estimated 52% share of first-line NSCLC, splitting the market into three PD-L1 cohorts ahead of its 2028 patent expiry.

Four approved immuno-oncology agents have divided the first-line NSCLC patient pool into distinct PD-L1 biomarker cohorts, each with a different dominant agent and different payer coverage criteria. Pembrolizumab controls the PD-L1 50% or greater monotherapy setting through five years of clinical and commercial precedent, holding an estimated 52% share, while combination regimens have set a different standard below that threshold. These cohorts are not interchangeable, and a single commercial strategy cannot address both.

US payer coverage criteria for immuno-oncology agents in NSCLC were written around the early KEYNOTE and CheckMate trials, and new entrants are evaluated against those precedents rather than their own trial designs. The evidence a payer will require at approval is already visible in existing coverage policies, and the window to shape that conversation runs 12 to 18 months pre-approval, not at launch. Mapping that landscape early is what lets a commercial team lock in position before strategy is set.

The coverage bar for a new entrant is set by precedent, not by its own trial design.

Five questions this report answers:

Q1 - What is the addressable NSCLC patient pool by PD-L1 cohort and line of therapy over five years?

Q2 - Which agents control which PD-L1 cohorts, and what clinical differentiation has actually moved prescribing share?

Q3 - What evidence thresholds are US payers applying, and does a new asset's trial design clear them?

Q4 - Where are the unmet needs current IO agents have not addressed among non-responder and progression cohorts?

Q5 - What are realistic patient-capture scenarios at Year 1, Year 3 and Year 5 by PD-L1 cohort?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#NSCLC #US #CompetitiveIntelligence #AXLRx #Oncology

Live report page:  https://axlrx.ai/nsclc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/